Mitsuhiro Rokuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitsuhiro Rokuda has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Musashi Fukuda
Astellas Pharma Inc. , Tokyo, Japan
3 shared publicationsYoshinori Kosakai
Medical Affairs Astellas Pharma Inc. Tokyo Japan
3 shared publications- Yoshiya Tanaka
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
3 shared publications Yuichiro Kaneko
Biostatistics Group , Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan
3 shared publications- Atsunori Kashiwagi
Department of Diabetes and Endocrinology Omi Medical Center Kusatsu Shiga Japan
2 shared publications - Daisuke Kato
Astellas Pharma Inc. , Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 19 December 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (3) , 374-387
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium‐glucose cotransporter 2 inhibitors vs dipeptidyl peptidase‐4 inhibitors in Japan: A real‐world administrative database analysis
Aims/Introduction: Healthcare resource utilization (HCRU) and healthcare costs are important factors to consider when selecting appropriate treatment for type 2 diabetes mellitus. We compared the HCRU and healthcare costs of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) vs dipeptidyl peptidase‐4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus in Japan.Materials and Methods: This was a Japanese retrospective cohort study conducted using the JMDC Claims Database (January 1, 2015–December 31, 2021). Patients newly treated with an SGLT2i (31,872 patients) or a DPP4i (73,279 patients) were matched 1:1, using propensity score, after excluding patients without continuous SGLT2i or DPP4i prescriptions after the index date. HCRU and healthcare costs were compared between the treatment groups in the full cohort and subcohorts/subgroups of different baseline characteristics, including body mass index (BMI).Results: After matching, patient characteristics were well balanced (17,767 patients each). Patients receiving an SGLT2i vs those receiving a DPP4i had significantly lower numbers of hospitalizations per person per month (PPPM) and outpatient visits PPPM, and had shorter lengths of stay per hospitalization. Healthcare costs, including all‐cause overall healthcare costs PPPM and all‐cause hospitalization costs PPPM, were generally lower in patients receiving an SGLT2i than those receiving a DPP4i. Similar results were observed among patients with a higher BMI but not among patients with a lower BMI.Conclusions: SGLT2i were associated with lower HCRU and healthcare costs than DPP4i, suggesting economic benefits with SGLT2i vs DPP4i in type 2 diabetes mellitus management.
- 19 December 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (3) , 374-387
Open AccessHealthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium‐glucose cotransporter 2 inhibitors vs dipeptidyl peptidase‐4 inhibitors in Japan: A real‐world administrative database analysis
Aims/Introduction: Healthcare resource utilization (HCRU) and healthcare costs are important factors to consider when selecting appropriate treatment for type 2 diabetes mellitus. We compared the HCRU and healthcare costs of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) vs dipeptidyl peptidase‐4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus in Japan.Materials and Methods: This was a Japanese retrospective cohort study conducted using the JMDC Claims Database (January 1, 2015–December 31, 2021). Patients newly treated with an SGLT2i (31,872 patients) or a DPP4i (73,279 patients) were matched 1:1, using propensity score, after excluding patients without continuous SGLT2i or DPP4i prescriptions after the index date. HCRU and healthcare costs were compared between the treatment groups in the full cohort and subcohorts/subgroups of different baseline characteristics, including body mass index (BMI).Results: After matching, patient characteristics were well balanced (17,767 patients each). Patients receiving an SGLT2i vs those receiving a DPP4i had significantly lower numbers of hospitalizations per person per month (PPPM) and outpatient visits PPPM, and had shorter lengths of stay per hospitalization. Healthcare costs, including all‐cause overall healthcare costs PPPM and all‐cause hospitalization costs PPPM, were generally lower in patients receiving an SGLT2i than those receiving a DPP4i. Similar results were observed among patients with a higher BMI but not among patients with a lower BMI.Conclusions: SGLT2i were associated with lower HCRU and healthcare costs than DPP4i, suggesting economic benefits with SGLT2i vs DPP4i in type 2 diabetes mellitus management.
- Open Access
- 12 December 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (3) , 997-1007
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Aim: To compare the effects of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) versus dipeptidyl peptidase‐4 inhibitors (DPP4is) on liver function in patients with type 2 diabetes (T2D) in Japan. Materials and Methods: This was a Japanese retrospective cohort study using the RWD Database (1 January 2015 to 24 September 2021). Patients newly treated with an SGLT2i or a DPP4i were matched 1:4 (SGLT2i:DPP4i) using propensity score. The primary endpoint was the change from baseline to 1 year after the index date in alanine aminotransferase (ALT). Secondary endpoints included change from baseline in various laboratory test results, including the Fibrosis‐4 (FIB‐4) index, aspartate aminotransferase, gamma‐glutamyl transpeptidase (GGT), albumin and HbA1c. Endpoints were compared between treatment groups using Welch's t ‐test in the full population and in subgroups stratified by baseline characteristics. Results: Baseline characteristics of 955 and 3063 matched patients newly treated with an SGLT2i and a DPP4i, respectively, were well balanced. Patients receiving an SGLT2i had significantly greater reductions in ALT, FIB‐4 index and GGT and a significantly greater increase in albumin than patients receiving a DPP4i. A significantly greater change from baseline in ALT was observed in the SGLT2i group than in the DPP4i group among subgroups with lower baseline FIB‐4 index and HbA1c. Conclusions: In this study, improvements in various measures, including ALT, the FIB‐4 index, GGT and albumin, were observed with SGLT2is compared with DPP4is, suggesting that SGLT2is may provide hepatoprotective benefits, including the prevention of liver fibrosis, in patients with T2D in Japan.
- 12 December 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (3) , 997-1007
Open AccessComparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Aim: To compare the effects of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) versus dipeptidyl peptidase‐4 inhibitors (DPP4is) on liver function in patients with type 2 diabetes (T2D) in Japan. Materials and Methods: This was a Japanese retrospective cohort study using the RWD Database (1 January 2015 to 24 September 2021). Patients newly treated with an SGLT2i or a DPP4i were matched 1:4 (SGLT2i:DPP4i) using propensity score. The primary endpoint was the change from baseline to 1 year after the index date in alanine aminotransferase (ALT). Secondary endpoints included change from baseline in various laboratory test results, including the Fibrosis‐4 (FIB‐4) index, aspartate aminotransferase, gamma‐glutamyl transpeptidase (GGT), albumin and HbA1c. Endpoints were compared between treatment groups using Welch's t ‐test in the full population and in subgroups stratified by baseline characteristics. Results: Baseline characteristics of 955 and 3063 matched patients newly treated with an SGLT2i and a DPP4i, respectively, were well balanced. Patients receiving an SGLT2i had significantly greater reductions in ALT, FIB‐4 index and GGT and a significantly greater increase in albumin than patients receiving a DPP4i. A significantly greater change from baseline in ALT was observed in the SGLT2i group than in the DPP4i group among subgroups with lower baseline FIB‐4 index and HbA1c. Conclusions: In this study, improvements in various measures, including ALT, the FIB‐4 index, GGT and albumin, were observed with SGLT2is compared with DPP4is, suggesting that SGLT2is may provide hepatoprotective benefits, including the prevention of liver fibrosis, in patients with T2D in Japan.
- Open Access
- 14 December 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (3) , 404-416
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
Aims/Introduction: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown beneficial effects on cardiometabolic risk factors (hemoglobin A1c, body mass index, systolic blood pressure) in patients with type 2 diabetes mellitus. We compared combined cardiometabolic effects of SGLT2i on hemoglobin A1c, body mass index and systolic blood pressure versus dipeptidyl peptidase‐4 inhibitors (DPP4i) in Japanese patients with type 2 diabetes mellitus.Materials and Methods: This Japanese retrospective cohort study used the JMDC claims database. Patients newly treated with an SGLT2i (n = 18,936) or DPP4i (n = 55,484) were enrolled (January 2015–March 2020) and matched 1:1 using the propensity score. The primary end‐point was the proportion of patients achieving a composite outcome (i.e., simultaneous absolute/percent reduction in hemoglobin A1c ≥0.5%, body mass index ≥3% and systolic blood pressure ≥2 mmHg) 1 year after first SGLT2i or DPP4i prescription; Mantel–Haenszel common risk difference and its 95% confidence interval were estimated. Other end‐points included treatment persistence, with the associated hazard ratio calculated using the Cox proportional hazards model.Results: After matching, patient characteristics were balanced (7,302 patients each). The proportion of patients achieving the composite outcome was significantly greater in patients receiving an SGLT2i than those receiving a DPP4i (31.0% [1,279/4,120] vs 12.9% [524/4,070], risk difference 18.6%, 95% confidence interval 16.3, 20.9, P < 0.001). Risk of treatment discontinuation was significantly lower in the SGLT2i group than in the DPP4i group (hazard ratio 0.85, 95% confidence interval 0.81, 0.90, P < 0.001).Conclusions: In the present study, SGLT2i showed favorable cardiometabolic risk reduction and longer treatment persistence than DPP4i in Japanese patients with type 2 diabetes mellitus.
- 14 December 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (3) , 404-416
Open AccessCardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
Aims/Introduction: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown beneficial effects on cardiometabolic risk factors (hemoglobin A1c, body mass index, systolic blood pressure) in patients with type 2 diabetes mellitus. We compared combined cardiometabolic effects of SGLT2i on hemoglobin A1c, body mass index and systolic blood pressure versus dipeptidyl peptidase‐4 inhibitors (DPP4i) in Japanese patients with type 2 diabetes mellitus.Materials and Methods: This Japanese retrospective cohort study used the JMDC claims database. Patients newly treated with an SGLT2i (n = 18,936) or DPP4i (n = 55,484) were enrolled (January 2015–March 2020) and matched 1:1 using the propensity score. The primary end‐point was the proportion of patients achieving a composite outcome (i.e., simultaneous absolute/percent reduction in hemoglobin A1c ≥0.5%, body mass index ≥3% and systolic blood pressure ≥2 mmHg) 1 year after first SGLT2i or DPP4i prescription; Mantel–Haenszel common risk difference and its 95% confidence interval were estimated. Other end‐points included treatment persistence, with the associated hazard ratio calculated using the Cox proportional hazards model.Results: After matching, patient characteristics were balanced (7,302 patients each). The proportion of patients achieving the composite outcome was significantly greater in patients receiving an SGLT2i than those receiving a DPP4i (31.0% [1,279/4,120] vs 12.9% [524/4,070], risk difference 18.6%, 95% confidence interval 16.3, 20.9, P < 0.001). Risk of treatment discontinuation was significantly lower in the SGLT2i group than in the DPP4i group (hazard ratio 0.85, 95% confidence interval 0.81, 0.90, P < 0.001).Conclusions: In the present study, SGLT2i showed favorable cardiometabolic risk reduction and longer treatment persistence than DPP4i in Japanese patients with type 2 diabetes mellitus.
- Open Access
- 10 March 2022
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 33 (1) , 73-80
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
To determine efficacy of peficitinib in reducing joint damage, and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis (RA). This post hoc analysis used data from a placebo-controlled, phase 3 trial (RAJ4) of peficitinib in patients with RA and inadequate response to methotrexate. Erosion and joint space narrowing (JSN) was assessed at baseline and at Week 28/early termination (ET) of treatment using the van der Heijde-modified Sharp method. Univariate logistic regression analysis of change from baseline in modified total Sharp score identified predictive factors with significant treatment interaction; the effects of these factors on treatment response were further evaluated using a multivariate model. The analyses included 481 patients. For most joint groups, peficitinib demonstrated reduced change from baseline at Week 28/ET in erosion and JSN scores versus placebo; a numerically greater effect was observed with peficitinib 150mg versus 100mg. Baseline C-reactive protein (CRP) and prednisolone dose were identified as clinically significant negative predictive factors: treatment effect decreased as CRP or prednisolone dose increased, for both peficitinib doses. : Peficitinib 100mg and 150mg reduced joint damage versus placebo, across almost all joint groups. Higher baseline CRP and/or prednisolone dose were associated with reduced peficitinib efficacy. : NCT02305849
- 10 March 2022
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 33 (1) , 73-80
Open AccessPost hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
To determine efficacy of peficitinib in reducing joint damage, and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis (RA). This post hoc analysis used data from a placebo-controlled, phase 3 trial (RAJ4) of peficitinib in patients with RA and inadequate response to methotrexate. Erosion and joint space narrowing (JSN) was assessed at baseline and at Week 28/early termination (ET) of treatment using the van der Heijde-modified Sharp method. Univariate logistic regression analysis of change from baseline in modified total Sharp score identified predictive factors with significant treatment interaction; the effects of these factors on treatment response were further evaluated using a multivariate model. The analyses included 481 patients. For most joint groups, peficitinib demonstrated reduced change from baseline at Week 28/ET in erosion and JSN scores versus placebo; a numerically greater effect was observed with peficitinib 150mg versus 100mg. Baseline C-reactive protein (CRP) and prednisolone dose were identified as clinically significant negative predictive factors: treatment effect decreased as CRP or prednisolone dose increased, for both peficitinib doses. : Peficitinib 100mg and 150mg reduced joint damage versus placebo, across almost all joint groups. Higher baseline CRP and/or prednisolone dose were associated with reduced peficitinib efficacy. : NCT02305849
- Open Access
- 10 September 2021
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 32 (4) , 708-717
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years
To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). This was a post hoc analysis of pooled data from one Phase 2b study and two Phase 3 studies and final data from a long-term extension study of peficitinib in Asian rheumatoid arthritis patients. Two pooled datasets were analysed (Phase 3 studies and Phase 2/3 studies). Univariate and multivariate Cox regression analyses explored relationships between exposure-adjusted incidence rate of SI and HZD, peficitinib dose, and baseline factors. Total peficitinib exposure for 1052 patients receiving once-daily peficitinib in the pooled Phase 2/3 Asian studies was 2998.9 patient-years. Exposure-adjusted incidence rates (95% confidence interval) of SI and HZD were 2.7 (2.2, 3.4) and 6.9 (6.0, 8.0) per 100 patient-years, respectively, in pooled Phase 2/3 studies. Advanced age was prognostic for SI and HZD, while baseline prednisolone dose was prognostic for SI. There was no temporal relationship between either adverse event and prolonged peficitinib administration. As expected in this peficitinib-treated population, older patients had increased risk of SI and HZD, and those receiving higher prednisolone doses had increased risk of SI.
- 10 September 2021
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 32 (4) , 708-717
Open AccessA pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years
To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). This was a post hoc analysis of pooled data from one Phase 2b study and two Phase 3 studies and final data from a long-term extension study of peficitinib in Asian rheumatoid arthritis patients. Two pooled datasets were analysed (Phase 3 studies and Phase 2/3 studies). Univariate and multivariate Cox regression analyses explored relationships between exposure-adjusted incidence rate of SI and HZD, peficitinib dose, and baseline factors. Total peficitinib exposure for 1052 patients receiving once-daily peficitinib in the pooled Phase 2/3 Asian studies was 2998.9 patient-years. Exposure-adjusted incidence rates (95% confidence interval) of SI and HZD were 2.7 (2.2, 3.4) and 6.9 (6.0, 8.0) per 100 patient-years, respectively, in pooled Phase 2/3 studies. Advanced age was prognostic for SI and HZD, while baseline prednisolone dose was prognostic for SI. There was no temporal relationship between either adverse event and prolonged peficitinib administration. As expected in this peficitinib-treated population, older patients had increased risk of SI and HZD, and those receiving higher prednisolone doses had increased risk of SI.
- Open Access
- 9 November 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (3) , 543-555
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [dat...
- 9 November 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (3) , 543-555
Open AccessA pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [dat...